APA (7th ed.) Citation

R, B., E, G., E, B., S, G., M, R., PA, T., . . . DYM, L. (2025). Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control-matched, phase 4 clinical study (BALISTAD). Journal of the American Academy of Dermatology, 92(5), 1132. https://doi.org/10.1016/j.jaad.2024.11.079

Chicago Style (17th ed.) Citation

R, Bissonnette, et al. "Dupilumab Treatment Restores Lesional and Nonlesional Skin Barrier Function in Adults and Adolescents with Atopic Dermatitis Irrespective of the Filaggrin Genotype: Results from an Open-label, Healthy-control-matched, Phase 4 Clinical Study (BALISTAD)." Journal of the American Academy of Dermatology 92, no. 5 (2025): 1132. https://doi.org/10.1016/j.jaad.2024.11.079.

MLA (9th ed.) Citation

R, Bissonnette, et al. "Dupilumab Treatment Restores Lesional and Nonlesional Skin Barrier Function in Adults and Adolescents with Atopic Dermatitis Irrespective of the Filaggrin Genotype: Results from an Open-label, Healthy-control-matched, Phase 4 Clinical Study (BALISTAD)." Journal of the American Academy of Dermatology, vol. 92, no. 5, 2025, p. 1132, https://doi.org/10.1016/j.jaad.2024.11.079.